Treatment with anti-programmed cell death 1 (PD-1) and anti-PD-1 ligand 1 (PD-L1) antibodies has demonstrated substantial anti-tumor activity in multiple tumor types and has changed the treatment guidelines for lung cancer (3–5). This evidence concerns the gene CD274 and neoplasm.